Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2007

View Archived Issues

Positive interim results of Wyeth and Progenics' phase I study of oral methylnaltrexone

Oncolytics enrolls patients in U.K. combination clinical trial of Reolysin/docetaxel

Recent patents disclose novel treatment options for psychological disorders

New pharmacological solutions for immunological disorders, claimed in recent patent literature

BioLineRx and University of Illinois to develop cancer apoptosis agent

DSMB recommends BioMS' phase II MBP-8298 trial for MS continues per protocol

New PET diagnostic claimed in recent patent literature

InterMune and Roche submit amended CTA for ITMN-191 for HCV

MERITstudy compares combinations of Combivir and maraviroc or efavirenz in R5 HIV-1 infection

Tolerability of topical microbicide SPL-7013 shown in healthy males

Switzerland approves Tasigna based on efficacy in CML patients nonresponsive to Glivec

Development of alfimeprase resumes for blood clot-related disorders

Revlimid launched in U.K.

Bausch & Lomb Ireland withdraws Retisert marketing authorization application

Eli Lilly Japan files Strattera for attention deficit hyperactivity disorder in pediatric patients

Head-to-head phase IV trial compares Aptivus and darunavir

DSMB completes interim analysis of phase III study of TroVax for renal cancer

ODAC recommends FDA waits for survival results of phase III satraplatin trial

FDA places hold on tgAAC94 phase I/II study for inflammatory arthritis

Cell Therapeutics acquires Systems Medicine; gains worldwide rights to brostallicin

ICAgen files IND for novel small molecule ICA-105665 for epilepsy

Mircera approved in E.U. for treatment of anemia associated with chronic kidney disease

Novel HBsAg secretion inhibitor presented at ASV2007

Abbott's nonrefrigerated Aluvia tablets approved in 19 African countries

Summit completes name change from VASTox

Combination of ANX-201 and NRTIs proves synergistic in vitro

Positive clinical and in vitro findings presented for PRO-140 at international AIDS conference

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...